Short answer
ADC Therapeutics SA (ADCT) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $19M (up 3.0% year over year) with net income of −$17M.
Q2 2026 key financials · XBRL
- Revenue
- $19M
- +3.0% YoY · −7.0% QoQ
- Net income
- −$17M
- +70.8% YoY · +49.8% QoQ
- Operating margin
- -136.4%
- EPS (diluted)
- −$0.11
- +78.0% YoY · +47.6% QoQ
Source: XBRL data from the ADC Therapeutics SA (ADCT) Q2 2026 10-Q on SEC EDGAR. USD.
ADC Therapeutics SA Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $19.248M, up 2.2% YoY from $18.839M
- Product revenue $18.634M, up 3.0% YoY from $18.085M on higher pricing
- Operating loss $25.414M, down 42.4% YoY from $44.147M
- Net loss $16.565M, down 70.8% YoY from $56.646M
- LOTIS-5 regulatory concerns over Grade 5 events and marginal treatment benefit; restructuring reduces workforce approximately 17%
Risk Factors
- New regulatory risk: FDA raised substantial concerns over LOTIS-5’s benefit-risk profile after increased Grade 5 adverse events and marginal treatment benefit
- Most material update: FDA or foreign regulators may require an additional confirmatory trial, delaying approval and consuming significant resources
- Compliance risk: ZYNLONTA’s accelerated 3L+ DLBCL approval could be withdrawn if LOTIS-5 fails to verify clinical benefit
- Near-term commercial risk: LOTIS-5 results could reduce ZYNLONTA sales and impair enrollment in other ZYNLONTA trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADC Therapeutics SA quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.